DAFNA Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.97M Sell
640,915
-5,000
-0.8% -$22.2K 0.63% 37
2026
Q2
$2.69M Buy
645,915
+277,500
+75% +$1.17M 0.51% 40
2026
Q1
$1.53M Sell
368,415
-7,500
-2% -$30.4K 0.35% 51
2025
Q4
$2.43M Sell
375,915
-136,674
-27% -$852K 0.56% 44
2025
Q3
$2.87M Buy
512,589
+370,589
+261% +$1.6M 0.71% 37
2025
Q2
$470K Hold
142,000
– – 0.13% 66
2025
Q1
$412K Buy
142,000
+15,000
+12% +$45.4K 0.12% 74
2024
Q4
$452K Sell
127,000
-462,561
-78% -$2.13M 0.11% 73
2024
Q3
$2.94M Buy
589,561
+59,561
+11% +$232K 0.69% 37
2024
Q2
$1.38M Buy
530,000
+30,000
+6% +$100K 0.33% 53
2024
Q1
$2.13M Buy
+500,000
New +$1.66M 0.48% 42

Other funds holding AQST

DAFNA Capital Management's AQST Position: Q3 2026 in Review

DAFNA Capital Management reduced its Aquestive Therapeutics (AQST) stake by 0.77% in Q3 2026, selling an estimated $22.2K and leaving 640,915 shares worth $2.97M. The position accounts for 0.63% of the portfolio, ranked #37.

DAFNA Capital Management first reported a position in AQST in Q1 2024 and has held it in 11 quarters since. 190 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • DAFNA Capital Management held 640,915 shares of Aquestive Therapeutics worth $2.97M as of Q3 2026.
  • DAFNA Capital Management sold 5,000 Aquestive Therapeutics shares in Q3 2026, an estimated $22.2K.
  • Aquestive Therapeutics made up 0.63% of DAFNA Capital Management's portfolio in Q3 2026, its #37 holding.
  • DAFNA Capital Management first reported a position in Aquestive Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 190 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on DAFNA Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.